In the last trading session, 1,394,632 Abeona Therapeutics Inc. (NASDAQ:ABEO) shares changed hands as the company’s beta touched 1.39. With the company’s per share price at $1.7 changed hands at -$0.01 or -0.01% during last session, the market valuation stood at $171.8 Million. ABEO’s last price was a discount, traded about -122.94% off its 52-week high of $3.79. The share price had its 52-week low at $0.99, which suggests the last value was 41.76% up since then. When we look at Abeona Therapeutics Inc.’s average trading volume, we note the 10-day average is 942.45 Million shares, with the 3-month average coming to 1.58 Million.
Analysts gave the Abeona Therapeutics Inc. (ABEO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.7. If we narrow down to specifics, the data shows that none out of 3 analysts rate the stock as a Sell, with a further none assigning it an Overweight rating. Of the remaining, none recommended ABEO as a Hold, 3 felt it is a Buy and none rated the stock as Underweight. Abeona Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.17.
Abeona Therapeutics Inc. (NASDAQ:ABEO) trade information
Although ABEO has turned red as seen at the end of in last trading. With action -0.58%, the performance over the past five days has been red. The jump to weekly highs of $1.836 on Monday, Jun 14 added 7.43% to the stock’s daily price. The company’s shares are showing year-to-date upside of 0.08%, with the 5-day performance at -0.07% in the red. However, in the 30-day time frame, Abeona Therapeutics Inc. (NASDAQ:ABEO) is 0.09% up. Looking at the short shares, we see there were 6.65 Million shares sold at short interest cover period of 4.21 days.
The consensus price target for the stock as assigned by Wall Street analysts is $5.67, meaning bulls need an upside of 233.53% from its current market value. According to analyst projections, ABEO’s forecast low is $4 with $8 as the target high. To hit the forecast high, the stock’s price needs a +370.59% upsurge from its current level, while the stock would need to tank 135.29% for it to hit the projected low.
Abeona Therapeutics Inc. (ABEO) estimates and forecasts
Data shows that the Abeona Therapeutics Inc. share is not performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot +4.29% over the past 6 months, a -21.82% in annual growth rate that is considerably lower than the industry average of 9.1%. But despite this, analysts have looked to lower expectations by downgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Abeona Therapeutics Inc. will drop -21.4%, while the growth in revenue is estimated to hit -112.5% for the next quarter. Year-over-year growth is forecast to reach -95% down from the last financial year.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.5%. The 2021 estimates are for Abeona Therapeutics Inc. earnings to increase by 40%, but the outlook for the next 5-year period is at 0% per year.
Abeona Therapeutics Inc. (NASDAQ:ABEO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 15% of Abeona Therapeutics Inc. shares while 32.75% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 38.53%. There are 117 institutions holding the Abeona Therapeutics Inc. stock share, with Adage Capital Partners GP L.L.C. the top institutional holder. As of Mar 30, 2021, the company held 8.09% of the shares, roughly 8.01 Million ABEO shares worth $15.05 Million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 5.03% or 4.98 Million shares worth $9.36 Million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 2059642 shares estimated at $3.87 Million under it, the former controlled 2.08% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.51% of the shares, roughly 1.5 Million shares worth around $2.81 Million.